Steven Gillis - PhaseRx Chairman of the Board
Chairman
Dr. Steven H. Gillis, Ph.D., is Independent Chairman of the Board of the Company. Dr. Gillis, has served as a chairman of our board of directors since 2008. Since 2005, Dr. Gillis was a managing director at ARCH Venture Fund, a VC firm. From 1994 to 2005, Dr. Gillis served as chief executive officer and chairman of the board of directors of Corixa Corporationrationration, which he cofounded in October 1994. Previously, Dr. Gillis served as a director, head of research and development, chief scientific officer and acting chief executive officer of Immunex Corporationrationration, which he cofounded, from 1981 until his departure in 1994. Dr. Gillis led the acquisition of Trubion Pharmaceuticals, Inc. by Emergent BioSolutions in the fall of 2010. Dr. Gillis currently serves as a director of Shire plc, Accelerator Corporationrationration, Oncofactor Corporationration, VBI Vaccines Inc., Pulmatrix, Inc. and serves as director and chairman of VentiRX Pharmaceuticals, Inc., Theraclone Sciences, Inc. and Lycera Corporationration Dr. Gillis previously served as a director at bluebird bio, Inc. from 2011 to 2015 since 2008.
| Age | 62 |
| Tenure | 16 years |
| Phone | 206-805-6300 |
| Web | http://www.phaserx.com |
Steven Gillis Latest Insider Activity
Tracking and analyzing the buying and selling activities of Steven Gillis against PhaseRx stock is an integral part of due diligence when investing in PhaseRx. Steven Gillis insider activity provides valuable insight into whether PhaseRx is net buyers or sellers over its current business cycle. Note, PhaseRx insiders must abide by specific rules, including filing SEC forms every time they buy or sell PhaseRx'sshares to prevent insider trading or benefiting illegally from material non-public information that their positions give them access to.
Steven Gillis over a year ago Acquisition by Steven Gillis of 75000 shares of VBI Vaccines subject to Rule 16b-3 |
PhaseRx Management Efficiency
The company has return on total asset (ROA) of (64.2) % which means that it has lost $64.2 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (228.17) %, meaning that it created substantial loss on money invested by shareholders. PhaseRx's management efficiency ratios could be used to measure how well PhaseRx manages its routine affairs as well as how well it operates its assets and liabilities.The company currently holds 5.44 M in liabilities with Debt to Equity (D/E) ratio of 264.1, indicating the company may have difficulties to generate enough cash to satisfy its financial obligations. PhaseRx has a current ratio of 2.1, suggesting that it is liquid enough and is able to pay its financial obligations when due. Debt can assist PhaseRx until it has trouble settling it off, either with new capital or with free cash flow. So, PhaseRx's shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like PhaseRx sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for PhaseRx to invest in growth at high rates of return. When we think about PhaseRx's use of debt, we should always consider it together with cash and equity.
Similar Executives
| Showing other executives | CHAIRMAN Age | ||
| Elaine Rosen | Assurant | 68 | |
| Scott Rager | Old Republic International | 69 | |
| Michael Long | Usio Inc | 72 | |
| James Kellogg | Old Republic International | 62 | |
| Louis Hoch | Usio Inc | 58 | |
| Douglas Dietrich | Minerals Technologies | 55 | |
| William Becker | QBE Insurance Group | 64 | |
| Marston Becker | QBE Insurance Group | 59 | |
| Michael Angelini | The Hanover Insurance | 73 | |
| Aldo Zucaro | Old Republic International | 80 | |
| Duane Dunham | Minerals Technologies | 79 | |
| Joseph Muscari | Minerals Technologies | 68 | |
| Michael Long | Arrow Electronics | 65 | |
| Rande Yeager | Old Republic International | 75 | |
| Cynthia Egan | The Hanover Insurance | 66 | |
Management Performance
| Return On Equity | -228.17 | |||
| Return On Asset | -64.2 |
PhaseRx Leadership Team
Elected by the shareholders, the PhaseRx's board of directors comprises two types of representatives: PhaseRx inside directors who are chosen from within the company, and outside directors, selected externally and held independent of PhaseRx. The board's role is to monitor PhaseRx's management team and ensure that shareholders' interests are well served. PhaseRx's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, PhaseRx's outside directors are responsible for providing unbiased perspectives on the board's policies.
| ShingYin Tsui, Senior Vice President - Finance, Secretary | ||
| Brian Atwood, Director | ||
| Sean Monahan, Director of Chemistry | ||
| John Schmidt, Director | ||
| Pat Stayton, Co-Founder | ||
| Steven Gillis, Chairman of the Board | ||
| Richard Ulevitch, Director | ||
| Paul Johnson, Chief Scientific Officer, Co-Founder, Director | ||
| Allan Hoffman, Co-Founder | ||
| Robert Overell, Co-Founder and Presidentident, CEO, Director | ||
| Peggy Phillips, Director | ||
| Michelle Griffin, Independent Director | ||
| Michael Houston, Vice President - Therapeutics Development | ||
| Oliver Press, Co-Founder | ||
| Mary Prieve, Director of Biology | ||
| Gordon Brandt, Chief Medical Officer | ||
| James Watson, Head of Corporate Development | ||
| Erin Cox, IR Contact Officer |
PhaseRx Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is PhaseRx a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -228.17 | |||
| Return On Asset | -64.2 | |||
| Current Valuation | 3.46 M | |||
| Shares Outstanding | 11.69 M | |||
| Shares Owned By Insiders | 11.22 % | |||
| Shares Owned By Institutions | 51.52 % | |||
| Number Of Shares Shorted | 8.39 K | |||
| Price To Earning | (0.79) X | |||
| Price To Book | 5.65 X | |||
| EBITDA | (12.96 M) |
Some investors attempt to determine whether the market's mood is bullish or bearish by monitoring changes in market sentiment. Unlike more traditional methods such as technical analysis, investor sentiment usually refers to the aggregate attitude towards PhaseRx in the overall investment community. So, suppose investors can accurately measure the market's sentiment. In that case, they can use it for their benefit. For example, some tools to gauge market sentiment could be utilized using contrarian indexes, PhaseRx's short interest history, or implied volatility extrapolated from PhaseRx options trading.
Becoming a Better Investor with Macroaxis
Macroaxis puts the power of mathematics on your side. We analyze your portfolios and positions such as PhaseRx using complex mathematical models and algorithms, but make them easy to understand. There is no real person involved in your portfolio analysis. We perform a number of calculations to compute absolute and relative portfolio volatility, correlation between your assets, value at risk, expected return as well as over 100 different fundamental and technical indicators.Build Optimal Portfolios
Align your risk with return expectations
Check out Your Equity Center to better understand how to build diversified portfolios. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in metropolitan statistical area. You can also try the Portfolio Optimization module to compute new portfolio that will generate highest expected return given your specified tolerance for risk.
Other Consideration for investing in PhaseRx Stock
If you are still planning to invest in PhaseRx check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the PhaseRx's history and understand the potential risks before investing.
| ETFs Find actively traded Exchange Traded Funds (ETF) from around the world | |
| Positions Ratings Determine portfolio positions ratings based on digital equity recommendations. Macroaxis instant position ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
| Competition Analyzer Analyze and compare many basic indicators for a group of related or unrelated entities | |
| Global Correlations Find global opportunities by holding instruments from different markets | |
| Watchlist Optimization Optimize watchlists to build efficient portfolios or rebalance existing positions based on the mean-variance optimization algorithm |